Lantern Pharma
LTRN
5 hedge funds and large institutions have $1.55M invested in Lantern Pharma in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.96% more ownership
Funds ownership: 0% → 1.96% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$1.55M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$19.8K |
| 3 |
TI
tru Independence
Portland,
Oregon
|
+$6.46K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
+$2.59K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ZCA
1
Zeke Capital Advisors
Berwyn,
Pennsylvania
| $1.52M | +$1.55M | +119,750 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $19K | +$19.8K | +1,533 | New |
|
|
3
US Bancorp
Minneapolis,
Minnesota
| $3K | +$2.59K | +200 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $2K | +$2.2K | +170 | New |
|
|
TI
5
tru Independence
Portland,
Oregon
| $6 | +$6.46K | +500 | New |
|
LTRN Hedge Fund Activity: Q2 2020 in Review
5 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q2 2020, worth a combined $1.55M.
Buyers outnumbered sellers: 5 funds opened new LTRN positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Zeke Capital Advisors, opening a new position worth an estimated $1.55M.
- 5 institutional investors held Lantern Pharma (LTRN) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $1.55M of Lantern Pharma stock for Q2 2020.
- 5 funds opened new Lantern Pharma positions in Q2 2020 and 0 closed out, a net change of +5 holders.
- The largest Lantern Pharma buyer in Q2 2020 was Zeke Capital Advisors, an estimated $1.55M added.
Based on aggregated 13F filings for Q2 2020.